Catheter Precision, Inc. (VTAK) P/E Ratio History
Historical price-to-earnings valuation from 2026 to 2026
Loading P/E history...
VTAK Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 9, 2026, Catheter Precision, Inc. (VTAK) trades at a price-to-earnings ratio of -0.1x, with a stock price of $0.83 and trailing twelve-month earnings per share of $-1.32.
Compared to the Healthcare sector median P/E of 21.9x, VTAK trades at a 101% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 176.0x.
Relative to the broader market, VTAK trades at a notable discount to the S&P 500 median P/E of 24.9x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our VTAK DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
VTAK P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $223M | 31.3 | 2.44 | +48% | |
| $80B | 27.8 | - | +55% | |
| $147B | 11.0Lowest | 0.37Best | +134%Best | |
| $98B | 21.1 | - | +31% | |
| $533B | 38.2 | - | -58% | |
| $109B | 34.0 | 2.29 | +8% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
See VTAK's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs VTAK Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare VTAK vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonVTAK — Frequently Asked Questions
Quick answers to the most common questions about buying VTAK stock.
Is VTAK stock overvalued or undervalued?
VTAK current P/E: -0.1x. 5-year average P/E: N/A. Percentile: N/A.
How does VTAK's valuation compare to peers?
Catheter Precision, Inc. P/E of -0.1x compares to sector median of 21.9x. The discount suggests lower growth expectations or higher risk.
What is VTAK's PEG ratio?
VTAK PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2026-2026.